BUSINESS

• JT to Return Rights to Gilead’s 6 HIV Agents in 2019, Get 63.1 Billion Yen
  November 30, 2018

• Kowa Reps Continue Heavy GP Detailing for Parmodia in August: Anterio
  November 30, 2018

• Fycompa Hits Primary Endpoint in Monotherapy PIII, Eisai Eyes Filing by March-End
  November 29, 2018

• Daiichi Sankyo, Roche to Collaborate on CDx Development for DS-8201
  November 29, 2018

• JCR Launches Japan’s 1st Fabrazyme Biosimilar
  November 29, 2018

• Daiichi Sankyo’s Herceptin Biosimilar Hits Shelves, Nippon Kayaku/Celltrion Earn Breast Cancer Nod
  November 29, 2018

• Takeda’s Brigatinib Bags European OK for 2nd Line ALK-Positive NSCLC
  November 29, 2018

• Dissident Shareholder Group Hails Ex-Takeda Chief’s Opposition to Shire Deal
  November 29, 2018

• Blincyto, Eybelis Now Available in Japan
  November 28, 2018

• Ono Submits Cancer Cachexia Treatment in Japan
  November 28, 2018

• Pola Orbis to Transfer All Shares of Pola Pharma to Sun Pharma Global, Aiming to Focus on Beauty Care Business
  November 28, 2018

• Sumitomo Dainippon Settles Latuda Patent Lawsuits in US, New 5-Year Biz Plan Due Out Next Spring
  November 28, 2018

• Keytruda Continues to Close in on Opdivo in July-September Global Sales
  November 27, 2018

• Poteligeo Approved in Europe for Mycosis Fungoides, Sézary Syndrome: Kyowa Kirin
  November 27, 2018

• HIV Drug Juluca Gets Japan Approval: ViiV
  November 27, 2018

• GSK, Kyowa Kirin Join Hands for HIF-PH Inhibitor Daprodustat
  November 26, 2018

• Astellas Grabs License to Gene Therapy JVS-100, with Acquisition also in Cards
  November 26, 2018

• Daiichi Sankyo’s FLT3 Inhibitor Quizartinib Earns FDA’s Priority Review Status
  November 26, 2018

• Dissident Takeda Shareholders Making Final Pitch to Thwart Shire Buyout
  November 26, 2018

• MHLW Approves Label Expansions for Praluent, Tremfya
  November 22, 2018

ページ

• « 先頭
• ‹ Prev
• …
• 371
• 372
• 373
• 374
• 375
• 376
• 377
• 378
• 379
• …
• Next ›
• 最終 »